AR043433A1 - Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos - Google Patents

Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos

Info

Publication number
AR043433A1
AR043433A1 ARP040100636A ARP040100636A AR043433A1 AR 043433 A1 AR043433 A1 AR 043433A1 AR P040100636 A ARP040100636 A AR P040100636A AR P040100636 A ARP040100636 A AR P040100636A AR 043433 A1 AR043433 A1 AR 043433A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
heteroaryl
aryl
substituted
Prior art date
Application number
ARP040100636A
Other languages
English (en)
Spanish (es)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR043433A1 publication Critical patent/AR043433A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ARP040100636A 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos AR043433A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR043433A1 true AR043433A1 (es) 2005-07-27

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040100636A AR043433A1 (es) 2003-02-27 2004-02-27 Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos
ARP040100635A AR043432A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
ARP040100629A AR043427A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion, y su empleo como medicamentos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP040100635A AR043432A1 (es) 2003-02-27 2004-02-27 Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
ARP040100629A AR043427A1 (es) 2003-02-27 2004-02-27 Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion, y su empleo como medicamentos

Country Status (34)

Country Link
US (5) US7365084B2 (US07259177-20070821-C00164.png)
EP (3) EP1599455B1 (US07259177-20070821-C00164.png)
JP (3) JP2006519199A (US07259177-20070821-C00164.png)
KR (3) KR20050105492A (US07259177-20070821-C00164.png)
CN (3) CN100439345C (US07259177-20070821-C00164.png)
AR (3) AR043433A1 (US07259177-20070821-C00164.png)
AT (3) ATE365159T1 (US07259177-20070821-C00164.png)
AU (3) AU2004215672B2 (US07259177-20070821-C00164.png)
BR (3) BRPI0407758A (US07259177-20070821-C00164.png)
CA (3) CA2517386A1 (US07259177-20070821-C00164.png)
CL (2) CL2004000392A1 (US07259177-20070821-C00164.png)
CO (2) CO5690580A2 (US07259177-20070821-C00164.png)
DE (4) DE10308355A1 (US07259177-20070821-C00164.png)
DK (3) DK1599452T3 (US07259177-20070821-C00164.png)
EC (2) ECSP055985A (US07259177-20070821-C00164.png)
ES (3) ES2287700T3 (US07259177-20070821-C00164.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00164.png)
IL (2) IL170316A (US07259177-20070821-C00164.png)
MA (3) MA27737A1 (US07259177-20070821-C00164.png)
MX (3) MXPA05008988A (US07259177-20070821-C00164.png)
NO (3) NO20054396L (US07259177-20070821-C00164.png)
OA (2) OA13035A (US07259177-20070821-C00164.png)
PA (1) PA8596801A1 (US07259177-20070821-C00164.png)
PE (3) PE20050292A1 (US07259177-20070821-C00164.png)
PL (3) PL378437A1 (US07259177-20070821-C00164.png)
PT (3) PT1599453E (US07259177-20070821-C00164.png)
RS (1) RS20050594A (US07259177-20070821-C00164.png)
RU (3) RU2005129992A (US07259177-20070821-C00164.png)
SA (1) SA04250153A (US07259177-20070821-C00164.png)
TN (2) TNSN05206A1 (US07259177-20070821-C00164.png)
TW (3) TW200500349A (US07259177-20070821-C00164.png)
UY (2) UY28210A1 (US07259177-20070821-C00164.png)
WO (3) WO2004076428A1 (US07259177-20070821-C00164.png)
ZA (2) ZA200505768B (US07259177-20070821-C00164.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
KR101398715B1 (ko) 2006-08-10 2014-05-27 가부시키가이샤 미모잭스 아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물
CN105732376A (zh) 2007-08-16 2016-07-06 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
UA104286C2 (uk) * 2008-02-29 2014-01-27 Нисан Кемикал Индастрис, Лтд. Спосіб одержання тіофенової сполуки та її проміжних сполук (варіанти)
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184780A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9707003A (pt) 1996-01-17 1999-07-20 Novo Nordisk As Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
ES2287016T3 (es) 1999-04-28 2007-12-16 Sanofi-Aventis Deutschland Gmbh Derivados de diaril-acido como ligandos del receptor ppar.
SK15522001A3 (sk) * 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
JP2003506365A (ja) 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン:セロトニンアゴニスト
PL353367A1 (en) 1999-09-01 2003-11-17 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
ES2215769T3 (es) 1999-12-03 2004-10-16 Astrazeneca Ab Forma cristalina de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico.
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
KR20080067009A (ko) 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
EA004244B1 (ru) 2000-04-25 2004-02-26 Киорин Фармасьютикал Ко., Лтд. Новый стабильный кристалл производного тиазолидиндиона и способ его получения
CN1430603A (zh) 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
SK17252002A3 (sk) 2000-06-09 2003-05-02 Aventis Pharma Deutschland Gmbh Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
EP1313716B1 (en) * 2000-08-23 2007-05-02 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
ATE349425T1 (de) 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
KR100718906B1 (ko) * 2000-12-25 2007-05-18 오노 야꾸힝 고교 가부시키가이샤 디히드로나프탈렌 유도체 화합물 및 이 화합물을 유효성분으로 하는 약제
WO2002064549A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
ES2275887T3 (es) * 2001-06-07 2007-06-16 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisoma (ppar).
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
UA76773C2 (uk) 2001-08-31 2006-09-15 Санофі-Авентіс Дойчланд Гмбх Діарилциклоалкільні похідні, спосіб їх одержання і їх застосування як ppar-активаторів
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Pparモジュレーターとして用いるためのウレアリンカー誘導体
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
CA2517381A1 (en) 2004-09-10
TNSN05206A1 (en) 2007-06-11
US20080167354A1 (en) 2008-07-10
OA13035A (en) 2006-11-10
CL2004000391A1 (es) 2005-01-07
CN1753881A (zh) 2006-03-29
US7872034B2 (en) 2011-01-18
DE10308355A1 (de) 2004-12-23
AU2004215672A1 (en) 2004-09-10
PL377735A1 (pl) 2006-02-20
RU2005129992A (ru) 2006-02-10
PT1599452E (pt) 2007-09-12
ATE430738T1 (de) 2009-05-15
CN1753879A (zh) 2006-03-29
JP2006519199A (ja) 2006-08-24
ZA200505768B (en) 2005-11-23
MA27742A1 (fr) 2006-02-01
PL378437A1 (pl) 2006-04-03
DE502004004139D1 (de) 2007-08-02
NO20054396D0 (no) 2005-09-22
AU2004215673A1 (en) 2004-09-10
TW200508210A (en) 2005-03-01
RU2005129995A (ru) 2006-01-27
KR20050106462A (ko) 2005-11-09
WO2004076426A1 (de) 2004-09-10
JP2006519194A (ja) 2006-08-24
AU2004215677B2 (en) 2010-01-07
ECSP055985A (es) 2006-01-16
HRP20050744A2 (en) 2006-09-30
UY28210A1 (es) 2004-09-30
US7365084B2 (en) 2008-04-29
EP1599452B1 (de) 2007-06-20
CL2004000392A1 (es) 2005-04-22
PT1599453E (pt) 2009-07-14
DK1599452T3 (da) 2007-10-01
CA2517386A1 (en) 2004-09-10
TNSN05204A1 (en) 2007-06-11
KR20050105492A (ko) 2005-11-04
CN100439345C (zh) 2008-12-03
EP1599452A1 (de) 2005-11-30
AU2004215677A1 (en) 2004-09-10
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
EP1599455A1 (de) 2005-11-30
DK1599453T3 (da) 2009-08-24
ECSP055986A (es) 2006-01-16
NO20054396L (no) 2005-11-11
PT1599455E (pt) 2009-09-29
US7259177B2 (en) 2007-08-21
BRPI0407758A (pt) 2006-02-14
ATE365159T1 (de) 2007-07-15
EP1599455B1 (de) 2009-07-01
WO2004076428A1 (de) 2004-09-10
ATE435217T1 (de) 2009-07-15
JP2006519193A (ja) 2006-08-24
US7335671B2 (en) 2008-02-26
HRP20050742A2 (en) 2006-09-30
MXPA05008988A (es) 2005-10-18
PL378130A1 (pl) 2006-03-06
CN1756748A (zh) 2006-04-05
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
US20040209920A1 (en) 2004-10-21
NO20054408D0 (no) 2005-09-22
PE20040959A1 (es) 2005-01-17
MXPA05008951A (es) 2005-11-04
CO5690578A2 (es) 2006-10-31
DE502004009690D1 (de) 2009-08-13
RU2005130002A (ru) 2006-01-27
CO5690580A2 (es) 2006-10-31
SA04250153A (ar) 2005-12-03
OA13034A (en) 2006-11-10
NO20054398L (no) 2005-11-02
MA27736A1 (fr) 2006-02-01
ZA200505765B (en) 2006-05-31
DE502004009453D1 (de) 2009-06-18
MA27737A1 (fr) 2006-02-01
BRPI0407907A (pt) 2006-02-14
WO2004076427A1 (de) 2004-09-10
AR043432A1 (es) 2005-07-27
NO20054398D0 (no) 2005-09-22
UY28209A1 (es) 2004-09-30
AR043427A1 (es) 2005-07-27
US20080015238A1 (en) 2008-01-17
BRPI0407814A (pt) 2006-02-14
ES2329366T3 (es) 2009-11-25
EP1599453A1 (de) 2005-11-30
CN100439347C (zh) 2008-12-03
EP1599453B1 (de) 2009-05-06
PE20050293A1 (es) 2005-05-24
RS20050594A (en) 2007-12-31
US20050101637A1 (en) 2005-05-12
ES2326418T3 (es) 2009-10-09
IL170314A (en) 2010-11-30
MXPA05008995A (es) 2005-10-18
TW200510352A (en) 2005-03-16
KR20050106461A (ko) 2005-11-09
AU2004215673B2 (en) 2009-10-01
ES2287700T3 (es) 2007-12-16
DK1599455T3 (da) 2009-11-09
CA2516620A1 (en) 2004-09-10
CN100398526C (zh) 2008-07-02
US20050215596A1 (en) 2005-09-29
AU2004215672B2 (en) 2010-01-07
TW200500349A (en) 2005-01-01
PE20050292A1 (es) 2005-05-24

Similar Documents

Publication Publication Date Title
AR043433A1 (es) Derivados de acido acetico sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR049521A1 (es) Derivados de pirrazol - pirimidina
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
CO6220952A2 (es) Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
AR037983A1 (es) Derivados de pirido [2,1-a] isoquinolina
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR071386A1 (es) Compuestos heterociclicos nitrogenados, inhibidores carbamato y urea de la 11-beta-hidroxiesteroide deshidrogenasa tipo 1(11 beta-hsd1),composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad,hipertension,trastornos cognitivos y otras enfermedades.
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
AR045386A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
AR077598A1 (es) Compuestos heterociclicos fusionados como modulares de canales ionicos
AR057350A1 (es) Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas
CO5540343A2 (es) Derivados de furano y tiofeno que activan receptores activados por el proliferador de la peroxisoma humana
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR045955A1 (es) Compuestos benzoimidazolicos
RU2008133306A (ru) Соединенные мостиковой связью n-циклические сульфонамидо-ингибиторы гамма-секретазы
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
CO6160312A2 (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico
PE20130155A1 (es) Derivados de ariletinilo
AR069804A1 (es) Agonistas del receptor glucocorticoide c20- c21 sustituido
AR053526A1 (es) Derivados del acido alcanoico arilcicloalqui-sustituidos, composicion farmaceutica y procedimiento para su preparacion
CO6460743A2 (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal
FB Suspension of granting procedure